Evidence map›Paper›PMID 39497124›Full record

ArticleStem cell research & therapy2024

Controlled release of hydrogel-encapsulated mesenchymal stem cells-conditioned medium promotes functional liver regeneration after hepatectomy in metabolic dysfunction-associated steatotic liver disease.

Naoya Kasahara, Takumi Teratani, Junshi Doi, Shinichiro Yokota, Kentaro Shimodaira, Yuki Kaneko, Hideyuki Ohzawa, Yasunaru Sakuma, Hideki Sasanuma, Yasuhiro Fujimoto and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Naoya Kasahara *Department of Surgery, Jichi Medical University, Shimotsuke, Japan.
Takumi Teratani *Division of Translational Research, Jichi Medical University, Shimotsuke, Japan. teratani@jichi.ac.jp.ORCID 0000-0001-9923-0305
Junshi DoiDepartment of Surgery, Japanese Red Cross Otsu Hospital, Otsu, Japan.
Shinichiro YokotaDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Kentaro ShimodairaDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Yuki KanekoDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Hideyuki OhzawaDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Yasunaru SakumaDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Hideki SasanumaDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Yasuhiro FujimotoDepartment of Transplant Surgery, Nagoya University Hospital, Nagoya, Japan.
Taizen UrahashiDepartment of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Hideyuki YoshitomiDepartment of Surgery, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Hironori YamaguchiDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Joji KitayamaDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.
Naohiro SataDepartment of Surgery, Jichi Medical University, Shimotsuke, Japan.

Funding

Japan Society for the Promotion of Science JP17K10563Japan Society for the Promotion of Science JP26461926Jichi Medical University Jichi Medical University Young Investigator Award
6 · The paper itself

Abstract

backgroundGlobally, prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing, and there is an urgent need to develop innovative therapies that promote liver regeneration following hepatectomy for this disease. Surgical excision is a key therapeutic approach with curative potential for liver tumors. However, hepatic steatosis can lead to delayed liver regeneration and higher post-operative complication risk. Mesenchymal stem cells-conditioned medium (MSC-CM) is considered a rich source of paracrine factors that can repair tissues and restore function of damaged organs. Meanwhile, hydrogels have been widely recognized to load MSC secretome and achieve sustained release. This study aimed to evaluate the therapeutic effect of hydrogel-encapsulated MSC-CM on liver regeneration following partial hepatectomy (PHx) in a rodent model of diet-induced hepatic steatosis.

methodsMale Lewis rats were fed with a methionine and choline-deficient diet. After 3 weeks of feeding, PHx was performed and rats were randomly allocated into two groups that received hydrogel-encapsulated MSC-CM or vehicle via the intra-mesenteric space of the superior mesenteric vein (SMV).

resultsThe regeneration of the remnant liver at 30 and 168 h after PHx was significantly accelerated, and the expressions of proliferating cell nuclear antigen were significantly enhanced in the MSC-CM group. MSC-CM treatment significantly increased hepatic ATP and β-hydroxybutyrate content at 168 h after PHx, indicating that MSC-CM fosters regeneration not only in volume but also in functionality. The number of each TUNEL- and cleaved caspase-3 positive nuclei in hepatocytes at 9 h after PHx were significantly decreased in the MSC-CM group, suggesting that MSC-CM suppressed apoptosis. MSC-CM increased serum immunoregulatory cytokine interleukin-10 and interleukin-13 at 30 h after PHx. Additionally, mitotic figures and cyclin D1 expression decreased and hepatocyte size increased in the MSC-CM group, implying that this mode of regeneration was mainly through cell hypertrophy rather than cell division.

conclusionsMSC-CM represents a novel therapeutic approach for patients with MASLD requiring PHx.

Indexed as

HepatectomyHydrogelsLiver RegenerationMesenchymal Stem CellsAnimalsCulture Media, ConditionedFatty LiverLiverMaleRatsRats, Inbred LewCulture Media, ConditionedHydrogelsAdipose tissue-derived mesenchymal stem cellsConditioned mediumControlled releaseHepatectomyHydrogelLiver regenerationNon-alcoholic fatty liver diseaseRegenerative medicine

Identifiers

PMID39497124
PMCPMC11536549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.